Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile. Patients then entered open-labeled extension phases, with Sandostatin LAR intramuscular (IM) injections every 4 weeks. These produced broadly constant octreotide concentrations with dose proportionality. Area fluctuations were minimal. Steady-state conditions were generally reached after the second to third injection. There was no evidence of downregulation with Sandostatin LAR over 1 year of study. Based on the pharmacokinetic/pharmacodynamic relationship of octreotide, a starting dose of 20 mg Sandostatin LAR and administrations every 4 weeks provide growth hormone (GH) control comparable to the thrice-daily subcutaneous (SC) injection regimen, which is commonly 0.3 to 0.6 mg/d. The reduction from the burden of two to three SC injections per day is a particular advantage of Sandostatin LAR, which is an attractive alternative to the approved Sandostatin injection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0026-0495(96)90075-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation exposure and protection advice after [Lu]Lu-DOTA-TATE therapy in China.
EJNMMI Res
November 2024
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Article Synopsis
- - The study examined radiation exposure in 30 patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with [Lu]Lu-DOTA-TATE in China, focusing on radiation safety for patients and healthcare workers.
- - Researchers measured external dose rates and radiation doses to nurses and surroundings during and after treatment, determining safe contact times for patients' family members and coworkers post-therapy.
- - The findings established guidelines for when patients can resume daily interactions with others and confirmed that radiation exposure to medical staff and the hospital environment remained below national safety limits.
Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report.
Oncol Lett
January 2025
Department of Radiotherapy, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, P.R. China.
Neuroendocrine neoplasms of the pancreas (pNENs) are rare. In February 2021, a 54-year-old woman was diagnosed with pNEN and multiple metastases within the liver. The patient, diagnosed with grade G2 neuroendocrine neoplasm (T4N0M1), underwent an ultrasonography-guided liver biopsy and radiofrequency ablation.
View Article and Find Full Text PDFOctreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience.
J Nephrol
December 2024
Chair of Nephrology, Department of Public Health, Federico II University, Naples, Italy.
Key Clinical Message: Pancreatic neuroendocrine tumors (PNETs) are rare and often misdiagnosed due to their vague symptoms and tumor heterogeneity. Early detection using computed tomography (CT) is essential, particularly in regions without access to advanced diagnostic tools like immunohistochemistry and genetic testing.
Abstract: Neuroendocrine tumors (NETs) are rare tumors in adults and extremely rare in the pediatric population, as pancreatic NETs (pNETs) have an incidence rate of <0.
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Clin Transl Oncol
September 2024
Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
Introduction: The somatostatin analogs (SSA) octreotide and lanreotide are a mainstay in the treatment of neuroendocrine tumors (NET). The two pivotal trials differed considerably in terms of patient characteristics and are not directly comparable. Further comparative data are lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!